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Abstract
Background: The value of KI67 in breast cancer prognostication has been questioned due to concerns on
the analytical validity of visual KI67 assessment and methodological limitations of published studies. Here, we
investigate the prognostic value of automated KI67 scoring in a large, multicentre study, and compare this with
pathologists’ visual scores available in a subset of patients.
Methods: We utilised 143 tissue microarrays containing 15,313 tumour tissue cores from 8088 breast cancer
patients in 10 collaborating studies. A total of 1401 deaths occurred during a median follow-up of 7.5 years.
Centralised KI67 assessment was performed using an automated scoring protocol. The relationship of KI67 levels
with 10-year breast cancer specific survival (BCSS) was investigated using Kaplan–Meier survival curves and Cox
proportional hazard regression models adjusted for known prognostic factors.
Results: Patients in the highest quartile of KI67 (>12 % positive KI67 cells) had a worse 10-year BCSS than patients
in the lower three quartiles. This association was statistically significant for ER-positive patients (hazard ratio (HR)
(95 % CI) at baseline = 1.96 (1.31–2.93); P = 0.001) but not for ER-negative patients (1.23 (0.86–1.77); P = 0.248)
(P-heterogeneity = 0.064). In spite of differences in characteristics of the study populations, the estimates of HR were
consistent across all studies (P-heterogeneity = 0.941 for ER-positive and P-heterogeneity = 0.866 for ER-negative).
Among ER-positive cancers, KI67 was associated with worse prognosis in both node-negative (2.47 (1.16–5.27)) and
node-positive (1.74 (1.05–2.86)) tumours (P-heterogeneity = 0.671). Further classification according to ER, PR and
HER2 showed statistically significant associations with prognosis among hormone receptor-positive patients
regardless of HER2 status (P-heterogeneity = 0.270) and among triple-negative patients (1.70 (1.02–2.84)). Model fit
parameters were similar for visual and automated measures of KI67 in a subset of 2440 patients with information
from both sources.
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Conclusions: Findings from this large-scale multicentre analysis with centrally generated automated KI67 scores
show strong evidence in support of a prognostic value for automated KI67 scoring in breast cancer. Given the
advantages of automated scoring in terms of its potential for standardisation, reproducibility and throughput,
automated methods appear to be promising alternatives to visual scoring for KI67 assessment.
Keywords: Breast cancer, Automated KI67, Visual KI67, Prognostication
Background
Despite endorsements by several international guidelines
[1, 2] KI67 is yet to gain widespread application as a
prognostic and/or predictive marker in breast cancer [3].
This is due, largely, to methodological variability in KI67
scoring (such as antibody type, specimen type, type of
fixative, antigen retrieval methods, method of scoring,
etc.), and limitations in the design and analyses of stud-
ies that have reported on this marker [3–7].
In the majority of settings, KI67 is evaluated visually
by a pathologist even though there is yet to be consensus
regarding which regions to score between the invasive
edge, hot spots or the entire spectrum of the whole sec-
tion or tumour core [8]. As a result, both the intra-
observer and, especially, the inter-observer reproducibil-
ity of visually derived KI67 scores have been shown to
be poor [9–11]. This has not only hampered inter-study
comparability for KI67, but has fuelled concerns regard-
ing its analytical validity [3]. To address some of the
methodological issues related to KI67 assessment, the
International KI67 in Breast Cancer Working Group
published recommendations aimed at the standardisa-
tion of the analytical processes for KI67 evaluation [8].
This panel, however, fell short of making recommenda-
tions regarding the preferred method of scoring for KI67
between visual and automated. Several reports suggest
that automated methods could address some of the
problems associated with visual scoring [11–19]. These
methods are high throughput and are not limited by
intra-observer variability. However, concerns exist re-
garding the accuracy of automated methods and the
prognostic power of KI67 derived using these methods
relative to that derived visually by pathologists. Few rela-
tively small studies have reported a head-to-head com-
parison between scores derived using both methods in
terms of prognostic properties, and the results from
these are conflicting [11, 17–19].
The majority opinion regarding the prognostic prop-
erty of KI67 derives mostly from reviews and meta-
analyses, which support its prognostic role in breast can-
cer [4–7, 20]. The meta-analyses by de Azambuja et al.
[6] involving 12,155 patients and by Stuart-Harris et al.
[7] which included over 15,000 patients represent two
comprehensive analyses on this subject. These are lim-
ited, however, by reported evidence of publication bias,
by significant between-study heterogeneity and by the
fact that most of the included studies utilised different
methodological approaches for KI67 evaluation. Further-
more, while the analysis by de Azambuja et al. [6] was
limited by its inclusion of only univariate hazard ratios,
that by Harris et al. [7] was limited by the small intersec-
tion between the sets of covariates in the included stud-
ies. In a population-based cohort of a cancer registry,
Inwald et al. [21] examined the prognostic role of KI67
in 3658 patients for whom KI67 was routinely measured
in clinical practice and reported significant associations
between KI67 and overall survival [21]. An important
strength of this analysis was that it utilised routinely
assessed KI67 measurements in a clinical setting. But
this was also limited by the heterogeneity of the KI67
analytical processes in the different laboratories involved
in the study. Nonetheless, KI67 has found use in a
variety of clinical and epidemiological scenarios, includ-
ing its endorsement by a number of international guide-
lines for use in treatment decision-making in ER-
positive breast cancer [1, 2] and its incorporation as part
of emerging prognostic tools such as the IHC4 score
[22, 23] and PREDICT, a breast cancer treatment benefit
tool [24].
In this study, we evaluate the value and robustness of
automated scoring of KI67 for large-scale, multicentre
studies of breast cancer prognostication. We centrally
generated an automated KI67 score from stained tissue
microarrays (TMAs), and assessed its prognostic value
overall for different subtypes of breast cancer. We also
compared the prognostic performance of automated and
visually derived KI67 scores in a subset of patients.
Methods
Study population and study design
This analysis was conducted within the Breast Cancer
Association Consortium [25], which is a large, ongoing
collaborative project involving study groups across the
globe. Figure 1 shows that we collected a total of 166
TMAs containing 19,039 cores, representing 10,005 pa-
tients from 13 study groups (Additional file 1: Table S1).
Ten study groups provided unstained TMAs which were
then stained and digitised in the Breakthrough Core
Pathology laboratory at the Institute of Cancer Research
(ICR) and the academic biochemistry laboratory of the
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Royal Marsden Hospital (RMH), London, UK. Two
groups (MARIE and PBCS) provided pre-stained TMAs
which were also digitised in our centre. One study
(SEARCH) provided TMA images acquired using a
similar Ariol technology (a digital image acquisition and
analysis system) to the one adopted for this analysis. Of
the 10,005 patients, 1917 were excluded on account of
failing predefined quality control checks (N = 946) or
due to absent data on follow-up times and/or vital status
(N = 971). As a result, a total of 8088 patients from 10
study groups with a median follow-up of 7.5 years and a
total of 1401 breast cancer specific deaths were used in
the survival analysis involving automated KI67. Of these,
2440 patients with pathologists’ visual KI67 scores in
addition to automated KI67 scores were used to extrapo-
late a visual from an automated cut-off point, following
which comparative survival analyses involving visual and
automated KI67 scores were conducted. Information on
other clinico-pathological characteristics of tumours in-
cluding histological grade, nodal status, tumour size,
stage, adjuvant systemic therapy (endocrine therapy and/
or chemotherapy) and other IHC markers (i.e. oestrogen
receptor (ER), progesterone receptor (PR) and human
epidermal growth factor receptor 2 (HER2)) were
obtained from clinical records. Additional Ariol HER2
data were obtained for a subset of patients with missing
clinical HER2 data but for whom data on ER and PR
were available (N = 403). All patients provided written
informed consent and all participating studies gained ap-
proval from the local ethical committees and institu-
tional review boards.
KI67 immunostaining
Sections were dewaxed using xylene and rehydrated
through graded alcohol (100, 90 and 70 %) to water.
Slides were then placed in a preheated (5 min, 800 W
microwave) solution of Dako Target Retrieval solution
pH 6.0 (S1699), microwaved on high power for 10 min
and then allowed to cool in this solution at room
temperature for 10 min. In the next stage, the slides
were placed on a Dako autostainer and stained using a
standard protocol with Dako MIB-1 diluted 1/50 and
visualised using the Dako REAL kit (K5001). The MIB-1
antibody was also adopted for the staining of the TMAs
Fig. 1 Study population and study design. We collected 166 TMAs containing 19,039 cores from 10,005 patients. Of these, 15 TMAs containing
1346 cores were selected as the training set and these were used to develop an automated scoring protocol that was validated against
corresponding computer-assisted visual (CAV) scores. Ultimately, this protocol was applied to the scoring of all 166 TMAs. Following automated
scoring, all cores that failed our priori defined quality control checks (including total nuclei count >50 and <15,000, and KI67 score = 100 %) were
excluded (N = 946 patients). For the purpose of survival analyses, all subjects with missing follow-up/survival data were also excluded (N = 971
patients). As a result, a total of 8088 patients were used in the survival analysis involving automated KI67 score. Furthermore, based on a subset
of patients (N = 2440) with pathologists’ KI67 scores in addition to the automated KI67 scores, we extrapolated a visual from an automated
cut-off point and used this to compare the prognostic performance of visual and automated KI67 scores in breast cancer. QC quality control,
TMA tissue microarray
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that were not part of those centrally stained at the ICR,
but at varying concentrations (PBCS = 1:500; MARIE =
1:400 and SEARCH = 1:200) (Additional file 1: Table S2).
KI67 scoring
KI67 scoring has been described previously [26], but
briefly all TMAs were digitised using the Ariol 50s
digital scanner. Fifteen TMAs were selected as a training
set. These were scored visually by a pathologist (MA)
using a computer-assisted visual (CAV) counting
method and used to validate the automated method.
The CAV method relied upon built-in features of the
Ariol digital system to count negative and positive nu-
clear populations within 250 μm× 250 μm squares sepa-
rated by grids. The standard CAV approach entailed the
counting of at least 1000 cells across the entire spectrum
of each core. In the majority of cores, more than 1000
cells were counted even though fewer than this number
was counted in a small minority. Overall, cores with
more than 500 cells were considered to be of satisfactory
quality. The CAV method is precise, prevents double
counting and was observed to have excellent intra-
observer reproducibility when a random subset of cores
(N = 111) were re-scored at an interval of 3 months from
the first time they were scored (observed agreement/
kappa = 96 %/0.90); good core-level agreements with two
other independent scorers (observed agreement/kappa:
CAV vs scorer 2 = 87 %/0.66; CAV vs scorer 3 = 84 %/
0.59; scorer 2 vs scorer 3 = 89 %/0.69) were also ob-
served in a randomly selected subset of 202 cores. Visual
scoring in the external TMAs involved both quantitative
and semi-quantitative methods. Each core from each pa-
tient was scored by two independent pathologists and
the KI67 score for each patient was then taken as the
average score from the two scorers across all cores for
that patient.
The automated scoring was performed using the Ariol
machine which has functionality that allows for the
automatic detection of malignant and non-malignant
nuclei using shape and size characteristics. Using colour
deconvolution, it also distinguishes between DAB-
positive and DAB-negative (haematoxylin) malignant
cells. To determine the negative and positive populations
of cells, an appropriate region of interest of the malig-
nant cell population in a core was demarcated and two
colours were selected to indicate positive and negative
nuclear populations. The appropriate colour pixels were
then selected to represent the full range of hue, satur-
ation and intensity that was considered representative of
the positive and negative nuclear classes [26]. Subse-
quently, the best shape parameters that discriminated
malignant and non-malignant cells according to their
spot width, width, roundness, compactness and axis ra-
tio were also selected. The data were divided into a
training and a validation subset and the automated and
visual scoring for KI67 showed good agreement (ob-
served agreement = 87 %; Kappa = 0.64) and discrimin-
atory accuracy (AUC = 85 %) in the validation subset,
hence allowing for the adoption of this method for the
scoring of all 166 TMAs.
Statistical methods
For patients with multiple cores from the same tumour,
we used the average KI67 score across valid cores to rep-
resent the % positive cells in that tumour. Descriptive
analyses of the distribution of KI67 according to clinical
and pathological characteristics of the patients were con-
ducted using the non-parametric Kruskal–Wallis equal-
ity of medians test for continuous measures and the
paired chi-squared test for categorical measures. The
relative survival probabilities for patients in different
quartiles of the KI67 distribution were compared using
Kaplan–Meier survival curves for the 10-year breast can-
cer specific survival (BCSS). To allow for prevalent can-
cers, time at risk was left-censored for study entry. It
was decided, a priori, not to make any assumptions on a
prognostic cut-off point for automated KI67 scores in
our dataset but instead to leverage on the continuous
values to observe a prognostic threshold. As a result, we
performed quartile analysis by dividing the continuous
KI67 scores into quartiles (Q1–Q4) and examining the
prognostic differences among the different quartiles
for all patients in the study. The 10-year BCSS was
determined using Kaplan–Meier survival curves and
Cox-proportional hazards regression models stratified
by ER status (positive vs negative) and according to
nodal status (positive vs negative) and other IHC
markers. The univariate Cox models were partially
adjusted for study group and age at diagnosis while
the multivariate models had further adjustments for
other known prognostic factors including histological
grade, tumour size, nodal status, morphology, ER, PR,
HER2 and adjuvant systemic therapy (endocrine and/
or chemotherapy). In the multivariate models, missing
values for other covariates were addressed using the
multiple imputation plus outcome (MI+) approach
[27]. Because of observed violation of the proportion-
ality assumption of the Cox model by automated
KI67, it was modelled as a time-varying covariate
using an extension of the Cox model that allows for
the inclusion of a coefficient (T) that varied as an ex-
ponential function of time. The log of the coefficient
is indicative of both the direction and the magnitude
of change in hazard ratio with time, such that if log
T < 1 then hazard falls with time, while if log T > 1
then hazard increases with time. Known violation of
the proportional hazards assumption by ER was ad-
dressed in the same way. Consistency of hazard ratio
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(HR) estimates across the different study groups was
evaluated using the I2 statistic, derived by performing
a fixed-effect meta-analysis of study-specific HR esti-
mates. To enable direct comparison between the vis-
ual and automated KI67 scores, we extrapolated a
visual from an automated cut-off point in a linear re-
gression model and used the resulting cut-off point
for all further analyses. All analyses were conducted
using STATA statistical software version 10 (Stata-
Corp, College Station, TX, USA). Statistical tests were
two-sided and P < 0.05 was considered statistically
significant.
Results
Description of study population and association between
automated KI67 score and other clinico-pathological
characteristics of breast cancer patients (N = 8088)
In all, a total of 143 TMAs containing 15,313 cores
from 8088 patients were used in this analysis, as
shown in Fig. 1. The studies included in this analysis
used different TMA designs (Table 1). More than half
(4431/55 %) of the patients had KI67 scores on at
least two cores and evaluation of dichotomous cat-
egories revealed concordant KI67 status in 83.7 % of
the patients. When we examined the distribution of
continuous KI67 scores among categories of the dif-
ferent clinical and pathological characteristics we ob-
served this to differ according to histological grade,
tumour size, morphology, ER status, PR status and
HER2 status, but not nodal status or stage at diagno-
sis (Fig. 2). The distribution of these characteristics
for patients with high KI67 (Q4 or >12 % positive
cells) and low KI67 (Q1–Q3) are shown in Additional
file 1: Tables S3 and S4 for ER-positive and ER-
negative patients, respectively.
Association between automated KI67 score and 10-year
BCSS among 8088 patients
Using continuous measures of KI67 categorised into
quartiles, we observed poorest survival in the highest
quartile, corresponding to 12 % positive cells, but little
difference in survival between the other three (Q1–Q3)
quartiles (log-rank P = 1.2 × 10−5; Fig. 3a). As a result,
the continuous KI67 value was dichotomised at the
threshold of 12 % in subsequent analyses. High KI67 was
significantly associated with worse 10-year BCSS overall
(log-rank P = 3.1 × 10−7) among ER-positive cancers
(log-rank P = 1.3 × 10−3) but not ER-negative cancers
(log-rank P = 0.35) (Fig. 3b–d, respectively). Similarly,
in multivariate models, high KI67 expression was sig-
nificantly associated with worse 10-year BCSS among
ER-positive cancers (HR at baseline = 1.96; 95 % CI =
1.31–2.93) but not ER-negative breast cancers (HR =
1.23; 95 % CI = 0.86–1.77; P-heterogeneity = 0.064)
(Table 2). Further stratification of ER-positive cancers
according to nodal status showed that high KI67 was
associated with worse survival in both node-negative
and node-positive cancers in multivariate analysis
(node-negative 2.47 (1.16–5.27); node-positive 1.74
(1.05–2.86); P-heterogeneity = 0.67) (Table 2). The asso-
ciation between KI67 and survival was significant
among ER-positive patients who did not receive chemo-
therapy (1.95 (1.18–3.21); P = 0.009) but not among
those who did (1.89 (0.84–4.29); P = 0.124; P-heterogen-
eity = 0.60). We found no evidence of between-study het-
erogeneity in estimates of HR for ER-positive patients (I2
= 0.0 %, P = 0.94) or ER-negative patients (I2 = 0.0 %, P =
0.86) (Additional file 2: Figure S1). Among hormone
receptor-positive breast cancers, the HR for KI67 was not
significantly different according to HER2 status (Table 2;
P-heterogeneity = 0.270). Modest evidence for a poorer
prognosis among high, relative to low, KI67 was also seen
Table 1 Description of study populations, TMA designs and patient characteristics for the 8088 patients included in this analysis
Study acronym Country Cases (N) Age at diagnosis,
mean (range)
TMAs Cores/patient
(range)
Cores/patient
(average)
Cores per
TMA
Core size
(mm)
Total cores
per study
ABCS The Netherlands 885 43 (19–50) 24 1–6 2.77 15–328 0.6 2449
ESTHER Germany 252 62 (50–75) 6 1–2 1.83 78–91 0.6 461
KBCP Finland 266 59 (30–92) 12 1–3 2.72 63–94 1.0 724
MARIE Germany 808 62 (50–75) 27 1–5 1.84 32–92 0.6 1490
MCBCS USA 437 58 (22–87) 7 1–8 3.73 131–301 0.6 1630
ORIGO The Netherlands 348 53 (22–87) 9 1–9 2.85 67–223 0.6 991
PBCS Poland 1068 56 (27–75) 22 1–2 2.21 66–145 1.0 2358
RBCS The Netherlands 225 45 (25–84) 6 1–5 2.85 134–199 0.6 642
SEARCH United Kingdom 3491 52 (24–70) 24 1–3 1.16 120–167 0.6 4037
kConFab Australia/New Zealand 308 45 (20–77) 6 1–2 1.72 65–114 0.6 531
Total 8088 53 (19–92) 143 1–9 1.89 15–328 0.6–1.0 15,313
TMA tissue microarray
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for triple-negative breast cancers (1.70 (1.02–2.84); P =
0.04). No significant associations with prognosis were
found for KI67 among HER2-positive (i.e. ER–/PR–/
HER2+) breast cancers (0.91 (0.60–1.36)) (Table 2).
Comparison of 10-year BCSS among 2440 patients with
both visual and automated quantitative KI67 scores
The automated cut-off point of 12 % positive cells
corresponded to a visual cut-off point of 24.2 % based
on a linear regression model comprising patients with
quantitative data on both methods. The visual cut-off
was rounded up to a cut-off point of 25 %. Strong evi-
dence (P < 0.0001) in support of a positive linear correl-
ation (r = 0.63) between automated and visual scores was
observed and continuous automated scores showed good
discriminatory accuracy against the visually determined
binary classes (AUC = 82 %, 95 % CI = 80–84 %)(Add-
itional file 3: Figure S2). Twenty-six percent of the pa-
tients were classified as having high visual KI67, in
contrast to 29 % for the automated KI67 scores; cross-
classification of visual and automated categories revealed
better specificity (84 %) than sensitivity (65.6 %) for the
automated score in classifying visually determined cat-
egories (Additional file 1: Table S5). High KI67 was asso-
ciated with worse survival in Kaplan–Meier curves
based on both automated (log-rank P = 9.8 × 10−6) and
visual (log-rank P = 3.8 × 10−14) KI67 scores even though
attenuation of the difference between strata was
observed for automated KI67 scores (Additional file 4:
Figure S3). In two separate models for visual and auto-
mated KI67 scores each adjusted for age at diagnosis
and study group we observed stronger evidence for an
association between KI67 and survival for the visual
KI67 score than for the automated KI67 score (Table 3).
Analysis of model fit revealed similar parameters for
both scores, however, especially in ER-positive breast
cancers (AIC/BIC: visual = 2656/2618; automated = 2675/
2638) (Table 3). When we performed further adjustments
for other prognostic factors in multivariate Cox models of
imputed datasets, we observed both visual and automated
KI67 scores to be significantly associated with survival for
all patients (HR (95 % CI): visual = 1.75 (1.23–2.49); auto-
mated = 1.61 (1.14–2.28)) and for ER-positive patients
(visual = 2.30 (1.34–3.94); automated = 2.10 (1.28–3.47)),
but not for ER-negative patients (visual = 1.63 (0.97–2.72);
automated = 1.28 (0.79–2.05)) (Table 3).
Discussion
Findings from our analysis provide strong evidence in
support of a prognostic relationship for automated KI67
scoring in ER-positive (node-negative and node-positive)
patients that is independent of tumour grade and other
prognostic factors. Even though our data suggested a
larger magnitude of the association between KI67 and
survival among the node-negative patients, the differ-
ence between node-positive and node-negative was not
Fig. 2 Distribution of continuous KI67 scores according to categories of other clinical and pathological variables. Significant differences were seen
in the distribution of automated KI67 scores according to categories of histological grade, tumour size, morphology, ER status, PR status and
HER2 status, but not nodal status or stage. ER oestrogen receptor, HER2 human epidermal growth factor receptor 2, PR progesterone receptor
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statistically significant. Involving over 8000 patients from
multiple centres internationally, this represents the lar-
gest study that has evaluated the prognostic value of au-
tomated KI67 scoring in breast cancer to date.
Furthermore, the large sample size allowed us to evalu-
ate its prognostic value in a number of breast cancer
subtypes including ER+ (node-negative and node-
positive), ER–, ER+ and/or PR+ (HER2+ or HER2–), ER–/
PR– and HER2+ (i.e. HER2-enriched) and triple-negative
breast cancers.
Our findings suggest that automated KI67 scoring is
an analytically valid approach to generating KI67 scores.
This is particularly noteworthy given the growing need
to incorporate measures of KI67 in prognostic tools such
as the IHC4 score and PREDICT [23, 24]. These tools
are relatively cheap, readily available and utilise routinely
measured IHC markers and, in the case of PREDICT,
other routinely available patient data to provide informa-
tion that can help clinicians and patients make informed
decisions regarding the course of treatment. It is ac-
knowledged that prognostication in breast cancer is be-
coming increasingly more sophisticated and that a
number of multigene assays [28, 29] have been validated
for this purpose; however, their costs and proprietary
concerns limit their use in a large number of settings.
Moreover, findings from previous studies suggest that
some multigene assays may not perform better than rou-
tinely measured IHC markers. For instance, Cuzick et al.
[23] reported similar prognostic properties for the
Genomic Health recurrence score (GHI-RS, Oncotype
DX), a 21-gene panel test, and the IHC4 score in
their analysis of 1125 women from the TransATAC
study, and notably KI67 was assessed by image ana-
lysis in that study [23]. Nonetheless, the relative per-
formance of visual and automated KI67 scores in
relation to the IHC4 score or PREDICT can only be
assessed in studies that are specifically designed for
that purpose.
Fig. 3 Kaplan–Meier survival curves for the 10-year BCSS according to strata of automated KI67 scores, overall and by ER status. KM survival curves
for the association between KI67 and 10-year BCSS among: (a) quartiles of KI67 (Q1, <25th percentile; Q2, 25th–50th percentile; Q3, >50th to 75th
percentile; and Q4, >75th percentile; N = 8088); (b) dichotomous categories of KI67 (≤12 %/low and >12 %/high) overall (N = 8088 patients); (c)
ER-positive cancers (N = 5520 patients); and (d) ER-negative cancers (N = 2049 patients)
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In addition to lack of analytical validity, the prognostic
performance of KI67 has also been questioned due to
the design and analysis of studies that have reported
previously on this protein [3]. Our evaluation is a large-
scale, multicentre analysis which has adopted the recom-
mended laboratory processes for the staining and
Table 2 Hazard ratio (HR) and 95 % CI for the association between automated KI67 score and 10-year BCSS in partially and fully adjusted
models: analysis stratified overall and according to ER, nodal status and other immunohistochemical markers (N = 8088 patients)
Partially adjusteda Fully adjustedb
Patients (N) Deaths (N) HR (95 % CI) P value HR (95 % CI) P value
All cancers
Low KI67 6093 1030 1.00 (referent) 1.00 (referent)
High KI67 1995 371 2.32 (1.79–3.00) 6.34 × 10−11 1.47 (1.13–1.92) 0.004
Tc 0.89 (0.84–0.94) 3.20 × 10−5 0.93 (0.87–0.98) 0.010
ER-positive
Low KI67 4379 615 1.00 (referent) 1.00 (referent)
High KI67 1141 166 2.47 (1.63–3.72) 8.45 × 10−6 1.96 (1.31–2.93) 0.001
T 0.88 (0.81–0.96) 0.003 0.89 (0.82–0.97) 0.006
ER-negative
Low KI67 1271 320 1.00 (referent) 1.00 (referent)
High KI67 778 188 1.38 (0.97–1.97) 0.072 1.23 (0.86–1.77) 0.248
T 0.94 (0.86–1.02) 0.155 0.94 (0.87–1.03) 0.199
ER-positive/node-positive
Low KI67 1550 350 1.00 (referent) 1.00 (referent)
High KI67 408 94 2.22 (1.31–3.77) 0.003 1.74 (1.05–2.86) 0.031
T 0.91 (0.82–0.99) 0.044 0.91 (0.82–1.01) 0.075
ER-positive/node-negative
Low KI67 2399 205 1.00 (referent) 1.00 (referent)
High KI67 561 55 3.17 (1.43–6.99) 0.004 2.47 (1.16–5.27) 0.019
T 0.84 (0.71–0.98) 0.034 0.86 (0.73–0.99) 0.048
HRP/HER2–
Low KI67 3332 462 1.00 (referent) 1.00 (referent)
High KI67 831 114 1.69 (1.26–2.27) 2.42 × 10−4 1.49 (1.10–2.00) 0.009
T 0.94 (0.90–0.98) 0.004 0.94 (0.90–0.98) 0.004
HRP/HER2+
Low KI67 421 82 1.00 (referent) 1.00 (referent)
High KI67 157 36 1.96 (1.28–3.00) 9.70 × 10−4 1.59 (1.03–2.45) 0.035
T 0.94 (0.90–0.98) 0.004 0.94 (0.90–0.98) 0.004
HRN/HER2– (triple-negative)
Low kI67 565 142 1.00 (referent) 1.00 (referent)
High KI67 436 107 1.75 (1.06–2.90) 0.028 1.70 (1.02–2.84) 0.044
T 0.86 (0.75–0.98) 0.031 0.86 (0.75–0.99) 0.031
HRN/HER2+ (HER2-enriched)
Low KI67 227 85 1.00 (referent) 1.00 (referent)
High KI67 149 48 0.76 (0.37–1.55) 0.450 0.75 (0.36–1.57) 0.455
T 1.08 (0.90–1.29) 0.396 1.07 (0.90–1.29) 0.435
aPartially adjusted models—adjusted for age at diagnosis and study group
bFully adjusted models—further adjustment for histological grade, tumour size, nodal status, morphology, PR, HER2, systemic therapy (endocrine and/or chemotherapy)
and (for the model involving all patients) ER status. This model was based on 20 imputations performed to address missing values on other covariates
cLog of time-varying coefficient (if T < 1 then hazard falls with time, and if T >1 then hazard increases with time)
HRP hormone receptor-positive, HRN hormone receptor-negative, ER oestrogen receptor, HER2 human epidermal growth factor receptor 2, PR progesterone receptor
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scoring of KI67 [8]. All TMAs in our analysis were
stained using the MIB1 antibody (even though not all of
them were centrally stained in our centre) and scored
using a single automated algorithm. Our estimates of ~2-
fold and ~1.5-fold increased risk of mortality at baseline
for high versus low KI67 in univariate and multivariate
analyses, respectively, are similar to those reported by de
Azambuja et al. (HR = 1.95) and Harris et al. (HR = 1.42)
[6, 7] in their univariate and multivariate meta-analyses,
respectively. Stratification of our analysis according to
other IHC markers (in addition to ER) showed automated
KI67 to be prognostic in hormone receptor-positive can-
cers. These findings, together with our observation of the
prognostic value of KI67 in both node-negative and node-
positive ER-positive patients, support the decision by the
St Gallen International Expert Consensus to endorse KI67
for treatment decision-making in ER-positive early (1–3
axillary nodes) breast cancer patients [1]. We also ob-
served modest evidence in support of poorer survival
outcomes among high, relative to low, KI67 expressing
triple-negative subtypes of breast cancer. This finding is in
support of a previous report by Keam et al. [30]. Our
population of triple-negative breast cancers (N = 1001),
however, was 9.5 times larger than that of Keam et
al. (N = 105).
Comparative analysis of visual and automated KI67
scores showed a stronger survival association for the vis-
ual over the automated scores; however, differences were
generally modest. Given the advantages of automated
versus visual scoring in terms of its potential for stand-
ardisation, reproducibility and throughput, automated
methods appear to be promising alternatives to visual
scoring for KI67 assessment. A potential limitation to
the adoption of automated KI67 scoring in the clinical
setting is that misclassification of positive nuclei as nega-
tive or malignant nuclei as benign could lead to attenu-
ation of prognostic associations, an observation that has
been reported previously for ER and PR [31] and one
which we have also observed for KI67 in this analysis.
This can be mitigated, however, by stringent quality
Table 3 Univariate (partially adjusted) and multivariate (fully adjusted) hazard ratio (HR) and 95 % CI for the associations between
automated and visual KI67 scores with survival in breast cancer (N = 2440)
Partially adjusted modela Fully adjusted modelb
Visual Automated Visual Automated
Patients
(N)
Deaths
(N)
HR
(95 % CI)
P value Patients
(N)
Deaths
(N)
HR (95 % CI) P value HR
(95 % CI)
P
value
HR (95 % CI) P
value
Overall
Low KI67 1804 116 1.00
(referent)
1728 125 1.00 (referent) 1.00
(referent)
1.00 (referent)
High
KI67
636 78 2.40
(1.92–3.01)
2.20 × 10
−14
712 69 1.67
(1.33–2.10)
1.30 × 10
−5
1.75
(1.23–2.49)
0.002 1.61 (1.14–
2.28)
0.007
AICc 5050.4 5087.2
BICc 5090.8 5127.6
ER-positive
Low KI67 1,337 69 1.00
(referent)
1241 69 1.00 (referent) 1.00
(referent)
1.00 (referent)
High
KI67
282 27 2.40
(1.72–3.33)
2.00 × 10−7 378 27 1.47
(1.05–2.04)
0.024 2.30
(1.34–3.94)
0.002 2.10 (1.28–
3.47)
0.004
AIC 2618.8 2638.2
BIC 2656.8 2675.8
ER-negative
Low KI67 357 39 1.00
(referent)
392 48 1.00 (referent) 1.00
(referent)
1.00 (referent)
High
KI67
331 48 1.84
(1.30–2.62)
6.10 × 10−4 296 39 1.44 (1.02–
2.04)
0.043 1.62
(0.97–2.72)
0.066 1.28 (0.79–
2.05)
0.312
AIC 1755.7 1763.4
BIC 1787.4 1795.1
aPartially adjusted model—adjusted for age at diagnosis and study group only
bFully adjusted model—further adjustment for other prognostic factors including histological grade, tumour size, nodal status, ER, PR, HER2, morphological
subtype and systemic therapy (endocrine and/or chemotherapy). This model was based on 20 imputations performed to address missing values on
other covariates
cModel fit parameter
AIC Akaike information criterion, BIC Bayesian information criterion, ER oestrogen receptor, HR hazard ratio, HER2 human epidermal growth factor receptor 2,
PR progesterone receptor
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control processes or by the adoption of a synergistic ap-
proach that combines the benefits of both the automated
and visual scoring methods. One such approach is the
CAV scoring method which we developed for the visual
counting of negative and positive malignant nuclei. This
approach, a variation of which has been reported previ-
ously [15], exploits the advantages of both visual and
digital imaging tools by enabling the visual counting of
KI67-positive cells in well-defined areas of a tumour
within a computer microenvironment. This method is
limited, however, by the observation that it is time
consuming; as such, it may not be efficient if adopted
for the large-scale scoring of KI67 in epidemiological
studies, clinical trials or biomarker discovery studies.
Nonetheless, efforts are currently underway to standard-
ise the methods for the visual scoring of KI67 in core-
cuts.
We centrally generated KI67 scores on TMAs and
determined a threshold of 12 % positive cells of prog-
nostic relevance in our study population. However,
due to possible variations in the distribution of KI67
scores according to specimen type and among differ-
ent laboratories, this cut-off point may not apply to
other types of clinical samples or to other labora-
tories. As a result, pending international standardisa-
tion of the KI67 analytical processes, setting local
laboratory-specific cut-off points as recommended by
international guidelines [1] remains a pragmatic ap-
proach to determining ‘high’ and ‘low’ KI67. Further-
more, although our automated cut-off point of 12 %
positive cells was determined to correspond to a
visual score of 25 %, this may be related, at least in
part, to the fact that automated systems generally
count more cells than the visual evaluator, a reason
that has been proposed to explain differences in KI67
scores between visual and automated scoring and
different automated scoring approaches [26]. None-
theless, findings from a recent meta-analysis that
assessed the prognostic value of different cut-off levels of
KI67 suggest that a visual cut-off point >25 % provides
greater discrimination in mortality risk than other cut-off
points [32].
Some limitations of our analysis include the lack of
data on specific chemotherapeutic or endocrine agents
received by each patient, as a result of which we were
unable to account for the impact of a specific treatment
regimen on survival or to examine whether or not KI67
is predictive of response to specific chemotherapeutic
and/or endocrine agents. We were, however, able to ac-
count for whether or not patients received adjuvant sys-
temic treatment in all our analyses because more than
two-thirds of the patients had information on treatment.
This also allowed us to perform stratified analysis ac-
cording to whether or not chemotherapy was
administered. Also, we did not have data on disease-free
survival which may have been a more informative end
point than BCSS in early breast cancer. Our assessment
of KI67 on TMAs may mean that direct inference can-
not be drawn from our findings on other types of clinical
samples, especially whole sections [8]. This is because
KI67 scores are speculated to be lower for TMAs than
for whole sections and not many studies have assessed
the correlation between KI67 scores on TMAs and those
on whole sections. However, one such study by Kobier-
zycki et al. [33] involving 51 archival paraffin blocks of
invasive ductal carcinoma showed excellent correlation
(r = 0.91) between the TMAs and whole sections. Their
paper utilised three 0.6 mm core punches, however, and
this may explain the high correlation between KI67
scores on TMAs and whole sections that was observed
in that study. Nonetheless, the fact that more than half
(4431/55 %) of the patients in our analysis had KI67
scores on two or more cores, with 83 % of these showing
concordant KI67 status, should limit the impact of intra-
tumour heterogeneity of KI67 scores on our findings.
Conclusion
Our large, multicentre study indicates that automated
KI67 scoring provides prognostic information in breast
cancer that is independent of standard parameters. In
view of its potential for standardisation, throughput and
reproducibility, the automated method appears to be a
promising alternative to visual scoring for KI67. These
findings are important given the increasing need to in-
corporate measures of KI67 as part of tools that are
needed to refine prognostic scores for breast cancer pa-
tients; this is especially relevant for patients with ER-
positive, node-negative tumours, in order to aid deci-
sions on providing adjuvant chemotherapy. However,
further work is needed to standardise the staining and
scoring protocols for KI67. In doing so, the potential
benefits and drawbacks of automated versus visual scor-
ing systems should merit consideration. In light of this
we welcome ongoing efforts by the International Work-
ing Party on KI67 in Breast Cancer aimed at standard-
isation of the analytical processes for KI67.
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